

## **Anti-Human CCM-2**

Synonyms: CCM-2, malcavernin, cerebral cavernous malformation 2, OSM, C7orf22, PP10187

## PLEASE NOTE: ALWAYS CENTRIFUGE VIAL BEFORE OPENING

Size Order# Lot# Expiry Date

100 μg 4385.852.100 200 μg 4385.852.200

Please enquire for bulk quantities and other vial sizes.

## **Description**

Cerebral cavernous malformations (CCMs) are sporadically acquired or inherited vascular lesions of the central nervous system consisting of clusters of dilated thin-walled blood vessels that predispose individuals to seizures and stroke. Familial CCM is caused by mutations in KRIT1 (CCM1) or in malcavernin (CCM2). The roles of the CCM proteins in the pathogenesis of the disorder remain largely unknown. It was shown that the CCM1 gene product, KRIT1, interacts with the CCM2 gene product, malcavernin. Analogous to the established interactions of CCM1 and beta1 integrin with ICAP1, the CCM1/CCM2 association is dependent upon the phosphotyrosine binding (PTB) domain of CCM2. A familial CCM2 missense mutation abrogates the CCM1/CCM2 interaction, suggesting that loss of this interaction may be critical in CCM pathogenesis. CCM2 and ICAP1 bound to CCM1 via their respective PTB domains differentially influence the subcellular localization of CCM1. The data indicate that the genetic heterogeneity observed in familial CCM may reflect mutation of different molecular members of a coordinated signaling complex.

Source RabbitClone AB-Sbccju!JH

**Biological Activity** Western Blot: Use 1-5 μg/ml

## Reconstitution

Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.

Usage: For research use only. Not for use in diagnostic or therapeutic procedures. Not for human use.